Clinical trial disruption emerges as primary business concern related to COVID-19: Survey

25 February 2021 (Last Updated February 25th, 2021 15:05)

More than 1,200 clinical trials across the globe were disrupted due to the COVID-19 pandemic related lockdowns and restrictions on movement.

More than 1,200 clinical trials across the globe were disrupted due to the COVID-19 pandemic related lockdowns and restrictions on movement. Shortages in personal protective equipment across the world is affecting both clinical workers and trial participants.

GlobalData had conducted a survey to identify the primary business concerns of pharmaceutical companies related to COVID-19 outbreak.

Primary business concern related to COVID-19

Primary Business Concerns Related to the COVID-19 Outbreak

Clinical trial disruption emerged as the biggest business concern of the industry due to the pandemic according to 26% of the respondents. Safety of patients recruited in the trials and employee safety in such programmes were others concerns expressed by 19% and 17% of the respondents respectively.

Around 11% of the companies highlighted contract research organisation (CRO) disruptions, while another 11% said that impact on supply chain was their primary concern related to the coronavirus outbreak.

Business development and capital raising were primary concerns for 10% and 5% of the respondents.

A minority of 1% of the surveyed companies expressed other concerns.

The analysis is based on responses received from the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.